Lonza Consumer Health and Nutrition Strengthens Canadian Ingredient Distribution Network with Quadra

February 04, 2019

Morristown, NJ (USA), 4 February 2019 – Lonza today announced the expansion of its distribution agreement with Quadra Chemicals Ltd (Quadra) in Canada.

The newly expanded agreement allows Quadra to sell Lonza Consumer Health & Nutrition’s full range of consumer health and nutrition ingredients to customers in Canada, including its UC-II® undenatured type II collagen. Lonza’s Carnipure® L-Carnitine and ResistAid® natural immune support ingredients are already represented by Quadra in the Canadian market.

Beth Tormey, Sr. Vice President, Head of Global Business Unit, Lonza Consumer Health & Nutrition, commented: “Our expanded agreement with Quadra builds upon an existing five-year relationship with the company. At Lonza we carefully select our strategic partners to ensure that they fit with our strong quality ethos, as well as our customer-driven focus.”

Tormey added, “This latest development enables Quadra to add further science-backed ingredients, such as Lonza’s UC-II® undenatured type II collagen, to its existing portfolio, which will provide relevant manufacturers and brand owners in Canada even more choices when creating nutritional supplement formulations, which ultimately benefits consumers.”

Lonza’s UC-II® undenatured type II collagen ingredient has been shown in multiple published clinical studies[i][ii][iii] to support optimal joint health by improving joint comfort, mobility and flexibility. Further, because a single, once-a-day dose is just 40 mg, it is also easily incorporated into nutritional supplement combination formulations.

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma & Biotech segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com

Lonza Contact Details

Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540

Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.  

[i] Lugo JP, Saiyed ZM, Lane NE, “Efficacy and tolerability of an undenatured type ll collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study.” Nutr J. 2016;15:14.

[ii] Crowley DC, Lau FC, Sharma P, et al., “Safety and efficacy of undenatured type ll collagen in the treatment of osteoarthritis of the knee: a clinical trial.” Int J Med Sci. 2009;6:312-321.

[iii] Lugo JP, Saiyed ZM, Lau FC, et al., “Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers.” J lnt Soc Sports Nutr. 2013;10:48